AML will affect approximately 20,830 and kill 10,460 Americans in 2015. Tremendous progress has been made in identifying disease characteristics that cause a patient to have a higher or lower chance of cure following intense treatment, which often involves bone marrow transplantation. Now investigators at the University of Alabama at Birmingham have analyzed a database with 5,541 patients younger than 65 years of age to demonstrate that, in addition to age and disease characteristics, other “non-biological” patient characteristics also matter. The study is the largest to date to look at socioeconomic factors in outcomes of younger patients with AML.
Patients who were single or divorced, patients who were uninsured or were Medicaid beneficiaries, and patients who lived in areas with lower income had substantially elevated risks of dying prematurely. “We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” said Uma Borate, MD, lead author of the study, and assistant professor in the UAB Division of Hematology and Oncology.
The findings show that factors not necessarily related to care can have significant impacts on AML patients’ outcomes. “As physicians, we often emphasize more of the biology of the cancer, especially with the recent focus on personalized medicine. But we need to pay the same attention to resources available to our patients, as this greatly impacts their chances to survive leukemia,” said senior author Luciano Jose Costa, MD, PhD, associate professor in the UAB Division of Hematology and Oncology.
This will be especially important as the U.S. transitions to a healthcare system that ties physician and hospital payments to patient outcomes. “Taking from the results of this study, factors that have nothing to do with quality of care need to be accounted for when comparing predicted with actual outcomes–otherwise we will create a disincentive for hospitals and doctors to care for less privileged patients,” said Dr. Borate.
Media wishing to receive a PDF of this article may contact [email protected] (Would you prefer to access this paper instantly? You can register for a login to our Press Room here.)
Article: “Non-biological factors affecting survival in younger patients with acute myeloid leukemia.” Uma Borate, Shin Mineishi, and Luciano Jose Costa. CANCER; Published Online: September 14, 2015 (DOI: 10.1002/cncr.29436).
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology and course of human cancer. CANCER is published by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley’s global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company’s website can be accessed at http://www.wiley.com.
Evelyn Martinez (US) +1 201 748 6358
Tom Griffin (UK) +44 (0) 1865 476213